VivoSeq
Gastroenterology

Barrett Esophagus

2

Pipeline Programs↗

5

Active Trials↗

1

Companies Involved↗

Barrett Esophagus is an early-stage landscape with 2 programs across 1 company. The most active players are Sebela Pharmaceuticals Development LLC.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sebela Pharmaceuticals Development LLC

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 22

Itraconazole

Sebela Pharmaceuticals Development LLC

Placebo Administration

Roswell Park Cancer Institute

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Unknown status1 · 14%
Completed1 · 14%
Active, not recruiting1 · 14%
Not yet recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Repurposing Itraconazole for Secondary Prevention of Metaplasia and Primary Prevention of Cancer in Patients With High-risk Barrett's Esophagus in Combination With Ablation
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT06732388·76 enrolled
A Multicenter Randomized Trial of Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance (The SWAT-BE Study)
Recruiting·UUniversity of Colorado, Denver·Preclinical·NCT05530343·2,298 enrolled
A Controlled, Randomised Multicenter Study Comparing the Effectiveness of EndoRotor (New Treatment Technique) Versus Radiofrequency (Reference Technique) in Treating Barrett's Esophagus Complicated by Dysplasia
Recruiting·UUniversity Hospital, Angers·Preclinical·NCT04867590·140 enrolled
Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)
Active, not recruiting·UUniversity of North Carolina, Chapel Hill·Preclinical·NCT03554356·70 enrolled
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma- R01 Aim 1a Renewal (SOS5C Trial)
Not yet recruiting·MMayo Clinic·Preclinical·NCT07206589·1,010 enrolled
Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia
Completed·National Cancer Institute (NCI)·Phase 2·NCT01097304·36 enrolled
Erlotinib in Treating Patients With Barrett Esophagus
Unknown status·—·Phase 1·NCT00566800·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)